Board of Directors

Dr. Robert A. Vukovich, Chairman.
Dr. Vukovich is Chairman and founder of InfaCare and serves as Chairman, Founder and CEO of WellSpring Pharmaceutical Corporation, a closely held specialty pharmaceutical company. He is the former Founder, Chairman, and CEO of Roberts Pharmaceutical Corporation, a public company that merged with Shire Pharmaceutical Group in December 1999. He has over 30 years of drug development experience and was employed by Warner Lambert, E.R. Squibb and the Revlon Health Care Group prior to founding Roberts Pharmaceutical. Dr. Vukovich is a Trustee of Allegheny College, Meadville, PA. He is a graduate of Jefferson Medical College with a degree in clinical pharmacology and pathology. He has authored or co-authored over 100 scientific publications dealing with drug development and clinical pharmacology.

Peter Barrett, Ph.D., Atlas Venture.
Peter Barrett is a Senior Partner in the life sciences sector, and joined Atlas Venture in 2002. Previously, he was a co-founder and Executive Vice President and Chief Business Officer of Celera Genomics, positions he had held since 1998. Within two years of the founding of the company, Celera announced the first successful sequencing of the human genome. Peter currently sits on the Advisory Council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University and is a member of the Partners Healthcare Research Accelerator Program. Peter's past board appointments include Chairman of the Board of the Analytical and Life Science System Association, HuBit Genomix, Genecore, Roche Strategic Alliance, and Sciex Joint Venture. He currently sits on the boards of Alnylam and Momenta Pharmaceuticals. Peter received his Bachelor of Science in Chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his Ph.D. in Analytical Chemistry from Northeastern University.

Dan Burns, President & Chief Executive Officer.
Mr. Burns joined InfaCare Pharmaceutical as President and Chief Executive Officer in April 2007, bringing to the company more than 20 years of management experience in the pharmaceutical and biotechnology industries. Prior to joining InfaCare, from 2002 to 2007 Mr. Burns was a Corporate Officer at MannKind Corporation and held the positions of CEO PDC, President Commercial Operations, and President MannKind BioPharmaceuticals. He led the building of the Technosphere Technology Platform enabling the company to successfully complete a public offering in 2004. Mr. Burns served as Chief Executive Officer of HealthTalk Interactive, a pharmaceutical services firm, from 2000 to 2002. From 1998 to 1999 Mr. Burns served as Chief Executive Officer of ProScript, a biopharmaceutical company when the company filed an IND for Velcade and proceeded to the clinic. He subsequently negotiated the sale of ProScript to a public biopharmaceutical company. Mr. Burns served as President and Chief Operating Officer of Trophix Pharmaceuticals Inc. from 1997 to 1998 where he successfully merged Trophix with the largest public biopharmaceutical company in Canada. Prior to joining Trophix Mr. Burns held a number of senior executive positions both internationally and domestically with Bristol Myers Squibb. Mr. Burns is a Business/Marketing graduate from Mohawk College and holds a bachelor’s degree in Psychology from McMaster University.

William W. Crouse.
Since January 1994, Mr. Crouse has been a Managing Director of HealthCare Ventures, a venture capital firm with a focus on biotechnology firms. From 1987 to 1993, Mr. Crouse served as Worldwide President of Ortho Diagnostic Systems and a Vice President of Johnson & Johnson International. Before joining Johnson & Johnson, Mr. Crouse was a Division Director of DuPont Pharmaceuticals Company, where he was responsible for international operations and worldwide commercial development activities. Before joining Dupont, he served as President of Revlon Health Care Group's companies in Latin America, Canada, and Asia/Pacific. He also held management positions at E.R.Squibb & Sons, a pharmaceutical company. Mr. Crouse currently also serves as a director of the Medicines Company and several private biotechnology companies and as a member of the Boards of Trustees of Lehigh University and the New York Blood Center. Mr. Crouse received a B.S. in finance and economics from Lehigh University and an M.B.A. from Pace University.

Patrick Enright, Longitude Capital.
Mr. Enright is a founder and Managing Director of Longitude Capital. He focuses on investments in biotechnology. From 2002 through 2006, Mr.Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately held and publicly traded biotechnology companies, such as SUGEN, Inc. and Cephalon, Inc. Mr. Enright began his investment career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies. Mr. Enright also has significant life sciences operations experience. He was CFO and Senior Vice President Business Development of Valentis, Inc. (NASDAQ: VLTS) and Senior Vice President Finance and Business Development of Boehringer Mannheim Pharmaceuticals (now Hoffmann-La Roche). Mr. Enright began his life sciences career 23 years ago at Sandoz (now Novartis). He currently serves on the boards of Threshold Pharmaceuticals (NASDAQ:THLD), Sequenom (NASDAQ: SQNM), DiObex, Codexis, Horizon Therapeutics, MAP Pharmaceuticals, Prestwick Pharmaceuticals and Raven biotechnologies. Mr. Enright holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.S. in Biological Sciences from Stanford University.

Richard Vietor. Mr. Vietor is President of RRVietor LLC, a private consulting company focused on healthcare, which has been engaged as a Senior Advisor to Lehman Brothers, Inc. since September 2005. From April 2003 to September, 2005, Mr. Vietor was Vice President of Emdeon Corporation (formerly WebMD Corporation), a health care services company. From February 2002 to April 2003, Mr. Vietor was an industry consultant, specializing in providing advice on corporate strategy, financing and communications to specialty pharmaceutical and medical device companies. From April 1985 until February 2002, he was at Merrill Lynch, Inc., most recently serving as a Managing Director in Merrill Lynch’s Healthcare Investment Banking Unit. Previously, he was First Vice-President, Senior Analyst and Global Research Coordinator in Merrill Lynch’s Global Securities Research Division, specializing in research coverage of the pharmaceutical industry. Mr. Vietor received his B.A. from Yale University and his M.B.A. in finance from the Columbia University Graduate School of Business.

Harold R. Werner. Hal Werner is a Managing Director and Co-founder of HealthCare Ventures. Prior to the formation of HealthCare Ventures, Mr. Werner served as director of new ventures for Johnson & Johnson Development Corporation. Mr. Werner also has served as senior vice president of Robert S. First, Inc., an international health care consulting firm. Mr. Werner received his M.B.A. degree from Harvard University.